Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Talis Biomedical Corporation TLIS OTC

Other OTC • Healthcare • Medical - Devices • US • USD

SharesGrow Score
30/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Talis Biomedical Corporation (TLIS) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bearish — 1 Hold, 3 Sell.

TLIS Analyst Ratings

Sell
4
Ratings
1 Hold
3 Sell
Based on 4 analysts giving stock ratings to Talis Biomedical Corporation in the past 3 months
Rating breakdown
Hold
1 25%
Sell
3 75%
0%
Buy
0 analysts
25%
Hold
1 analysts
75%
Sell
3 analysts

People Also View

BVS
BVS
Bioventus Inc.
$9.91
+5.20%
 NPCE
NPCE
NeuroPace, Inc.
$15.35
+3.16%
 SGHT
SGHT
Sight Sciences, Inc.
$3.82
+3.52%
 VAPO
VAPO
Vapotherm, Inc.
$2.17
-0.46%
 TNON
TNON
Tenon Medical, Inc.
$0.81
-1.28%
 HSCS
HSCS
Heart Test Laboratories, Inc.
$1.97
-0.76%
 INVO
INVO
INVO Bioscience, Inc.
$0.83
-2.00%
 BBLG
BBLG
Bone Biologics Corporation
$1.26
+2.44%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message